3-(6,7-Dihydro-1-Methyl-7-Oxo-3-Propyl-1H-Pyrazolo[4,3-d]Pyrimidin-5-yl)-N-[2-(1-Methyl-2-Pyrrolidinyl)Ethyl]-4-Propoxybenzenesulfonamide 3-(6,7-二氢-1-甲基-7-氧代-3-丙基-1H-吡唑并[4,3-D]嘧啶-5-基)-N-[2-(1-甲基-2-吡咯烷基)乙基]-4-丙氧基苯磺酰胺
CAS 268203-93-6 MFCD11977944
化学结构图
SMILES: CN1CCCC1CCNS(=O)(=O)C1C=C(C2NC(=S)C3=C(N=2)C(CCC)=NN3C)C(=CC=1)OCCC
化学属性
| Mol. Formula | C25H36N6O4S |
|---|---|
| Mol. Weight | 516.66 |
别名和识别编码
| Chemical Name | 3-(6,7-Dihydro-1-Methyl-7-Oxo-3-Propyl-1H-Pyrazolo[4,3-d]Pyrimidin-5-yl)-N-[2-(1-Methyl-2-Pyrrolidinyl)Ethyl]-4-Propoxybenzenesulfonamide |
|---|---|
| CAS Number | 268203-93-6 |
| Synonym | 3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxybenzenesulfonamide DA 8159 Zydena |
| Chemical Name Translation | 3-(6,7-二氢-1-甲基-7-氧代-3-丙基-1H-吡唑并[4,3-D]嘧啶-5-基)-N-[2-(1-甲基-2-吡咯烷基)乙基]-4-丙氧基苯磺酰胺 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- Aromatics
- Heterocycles
- Pharmaceuticals
- Intermediates & Fine Chemicals,
产品应用
- An oral phosphodiesterase 5 inhibitor used for the treatment of erectile dysfunction.
相关文献及参考
- [2]. Zhao, C., et al., Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int, 2011. 107(12): p. 1943-7.
- Kim, T. et al.: Br. J. Clin. Pharmacol., 68, 43 (2009); Lee, C. et al.: J. Sex Med., 7, 2564 (2010); Bae, S.K. et al.: Biomed. Chrom., 22, 939 (2008);
- [1]. Paick, J.S., et al., The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med, 2008. 5(4): p. 946-53.
- [1]. Paick, J.S., et al., The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med, 2008. 5(4): p. 946-53.
- [2]. Zhao, C., et al., Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int, 2011. 107(12): p. 1943-7.
